(Q35947641)

English

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

ChEBI release 2020-05-28

essential hypertension

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Kazuaki Enya

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Kenkichi Sugiura

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Yoshinori Ikeda

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

26 January 2012

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hypertension Research

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

35

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

552-558

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Prediction of stroke by home "morning" versus "evening" blood pressure values: the Ohasama study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Importance of trough : peak ratios in treatment of blood pressure in post-myocardial infarction and heart failure settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

2 October 2017

Uncontrolled hypertension based on morning and evening home blood pressure measurements from the J-HOME study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

24 September 2018

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

24 September 2018

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348575

24 September 2018

Predicting Cardiovascular Risk Using Conventional vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.8

21 January 2018

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated hypertensive patients with well-controlled clinic blood pressure: the Jichi Morning Hypertension Research (J-MORE) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/HR.2012.8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35947641&oldid=2197990319"